Specific chemical modification of bacterial type i dehydroquinase-opportunities for drug discovery

Future Medicinal Chemistry

Volumn 7, Issue 17, 2015, Pages 2371-2383

  González Bello, Concepción ^a  

^a s n   (Spain)

Author keywords

molecular dynamics simulations; nucleophilic catalysis; virulence

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL ENZYME; FRUCTOSE BISPHOSPHATE ALDOLASE; LYASE INHIBITOR; TYPE I DEHYDROQUINASE; TYPE I DEHYDROQUINASE INHIBITOR; UNCLASSIFIED DRUG; 3-DEHYDROQUINATE DEHYDRATASE; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; HYDROLYASE;

ANTIBIOTIC RESISTANCE; BACTERIAL VIABILITY; BACTERIAL VIRULENCE; CATALYSIS; CHEMICAL MODIFICATION; DRUG DESIGN; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME MECHANISM; ENZYME MODIFICATION; ENZYME SUBSTRATE COMPLEX; NONHUMAN; NUCLEOPHILIC CATALYSIS; NUCLEOPHILICITY; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; ANTAGONISTS AND INHIBITORS; BACTERIUM; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; ENZYMOLOGY; GRAM NEGATIVE BACTERIUM; METABOLISM; PHYSIOLOGY; VIRULENCE;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL PROTEINS; DRUG DISCOVERY; DRUG RESISTANCE, BACTERIAL; GRAM-NEGATIVE BACTERIA; HYDRO-LYASES; VIRULENCE;

EID: 84949450906     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.15.145     Document Type: Review

References (77)

1. Fair RJ, Tor Y. Antibiotics and bacterial resistance in the 21st century. Perspect. Med. Chem. 6, 25-63 (2014).
2. Appelbaum PC. 2012 and beyond: potential for the start of a second pre-antibiotic era J. Antimicrob. Chemother. 67(9), 2062-2068 (2012).
3. Mckenna M. Antibiotic resistance: the last resort. Nature 499(7459), 394-396 (2013).
4. Fischbach MA, Walsh CT. Antibiotics for emerging pathogens. Science 325(5944), 1089-1093 (2009).
5. Walsh C. Molecular mechanisms that confer antibacterial drug resistance. Nature 406(6797), 775-781 (2000).
6. Boucher HW, Talbot GH, Bradley JS et al. Bad bugs, no drugs: no ESKAPE! an update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48(1), 1-12 (2009).
7. Amin AN, Deruelle D. Healthcare-associated infections, infection control and the potential of new antibiotics in development in the USA. Future Microbiol. 10(6), 1049-1062 (2015).
8. Cosgrove SE, Carmeli Y. The impact of antimicrobial resistance on health and economic outcomes. Clin. Infect. Dis. 36(11), 1433-1437 (2003).
9. Zaoutis TE. Antibiotic resistance: who will pay the bills Clin. Infect. Dis. 49(8), 1185-1186 (2009).
10. Fernandes P. The global challenge of new clases of antibacterial agents: an industry perspective. Curr. Opin. Pharmacol. 24(X), 7-11 (2015).
11. Levy SB, Marshall B. Antibacterial resistance worldwide: causes, challenges and responses. Nat. Med. 10(12 Suppl.), S122-S129 (2004).
12. Projan SJ. New (and not so new) antibacterial targets-from where and when will the novel drugs come Curr. Opin. Pharmacol. 2(5), 513-544 (2002).
13. Payne DJ, Gwynn MN, Holme DJ, Pompliano DL. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 6, 29-40 (2007).
14. Rasko DA, Sperandio V. Anti-virulence strategies to combat bacteria-mediated disease. Nat. Rev. 9, 117-128 (2010).
15. Clatworthy AE, Pierson E, Hung DT. Targeting virulence: a new paradigm for antimicrobial therapy. Nat. Chem. Biol. 3(9), 541-548 (2007).
16. Cegelski L, Marshall GR, Eldridge GR, Hultgren SJ. The biology and future prospects of antivirulence therapies. Nat. Rev. 6(1), 17-27 (2008).
17. Alksne LE. Virulence as a target for antimicrobial chemotherapy. Expert Opin. Investig. Drugs 11(6), 1149-1159 (2002).
18. Allen RC, Popat R, Diggle SP, Brown SP. Targeting virulence: can we make evolution-proof drugs Nat. Rev. Microbiol. 12, 300-308 (2014).
19. ÓConnell KM G, Hodgkinson JT, Sore HF, Welch M, Salmond GP C, Spring DR. Combating multidrugresistant bacteria: current strategies for the discovery of novel antibacterials. Angew. Chem. Int. Ed. Engl. 52(41), 10706-10733 (2013).
20. Heras B, Scanlon MJ, Martin JL. Targeting virulence not viability in the search for future antibacterials. Br. J. Clin. Pharmacol. 79(2), 208-215 (2015).
21. Hentzer M, Givskov M. Pharmacological inhibition of quorum sensing for the treatment of chronic bacterial infections. J. Clin. Invest. 112(9), 1300-1307 (2003).
22. Kalia VC. Quorum sensing inhibitors: an overview. Biotechnol. Adv. 31(2), 224-245 (2013).
23. Tacket CO, Hone DM, Curtiss III R et al. Comparison of the safety and immunogenicity of aroC aroD and cya crp Salmonella typhi strains in adult volunteers. Infect. Immun. 60(2), 536-541 (1992).
24. Karnell A, Cam PD, Verma N, Lindberg AA. AroD deletion attenuates Shigella flexneri strain 2457T and makes it a safe and efficacious oral vaccine in monkeys. Vaccine 11(8), 830-836 (1993).
25. Tacket CO, Hone DM, Losonsky G, Guers L, Edelman R, Levine MM. Clinical acceptability and immunogenicity of CVD 908 Salmonella typhi vaccine strain. Vaccine 10(7), 443-446 (1992).
26. Racz R, Chung M, Xiang Z, He Y. Systematic annotation and analysis of "virmugens"-virulence factors whose mutants can be used as live attenuated vaccines. Vaccine 31(5), 797-805 (2013).
27. Malcova M, Karasova D, Rychlik I. aroA and aroD mutations influence biofilm formation in Salmonellaenteritidis. FEMS Microb. Lett. 291(1), 44-49 (2009).
28. Dilts DA, Riesenfeld-Orn I, Fulginiti JP et al. Phase I clinical trials of aroA aroD and aroA aroD htrA attenuated Salmonella typhi vaccines; effect of formulation on safety and immunogenicity. Vaccine 18(15), 1473-1484 (2000).
29. Abell C. Enzymology and molecular biology of the shikimate pathway. In: Comprehensive Natural Products Chemistry Volume 1. Sankawa U (Ed.). Pergamon-Elsevier Science Ltd, Oxford, UK, 573-607 (1999).
30. Roberts F, Roberts CW, Johnson JJ et al. Evidence for the shikimate pathway in apicomplexan parasites. Nature 393(6687), 801-805 (1998).
31. Campbell SA, Richards TA, Mui EJ et al. A complete shikimate pathway in Toxoplasma gondii: an ancient eukaryotic innovation. Int. J. Parasit. 34(1), 5-13 (2004).
32. McConkey GA, Pinney JW, Westhead DR et al. Annotating the plasmodium genome and the enigma of the shikimate pathway. Trends Parasitol. 20(2), 60-65 (2004).
33. Bentley R. The shikimate pathway-a metabolic tree with many branches. Crit. Rev. Biochem. Mol. Biol. 25(5), 307-384 (1990).
34. Kleanthous CK, Deka R, Davis K et al. A comparison of the enzymological and biophysical properties of two distinct classes of dehydroquinase enzymes. Biochem. J. 282(Pt 3), 687-695 (1992).
35. Chauduri C, Ducan K, Graham LD, Coggins JR. Identification of the active-site lysine residues of two biosynthetic 3-dehydroquinases. Biochem. J. 275(1), 1-6 (1991).
36. Shneier A, Kleanthous C, Deka R, Coggins JR, Abell C. Observation of an imine intermediate on dehydroquinase by electrospray mass spectrometry. J. Am. Chem. Soc. 113(24), 9416-9418 (1991).
37. Price NC, Boam DJ, Kelly SM et al. The folding and assembly of the dodecameric type II dehydroquinases. Biochem. J. 338(1), 195-202 (1999).
38. Database for essential genes. www.essentialgene.org.
39. Lamichhane G, Freundlich JS, Ekins S, Wickramaratne N, Nolan ST, Bisha WR. Essential metabolites of Mycobacterium tuberculosis and their mimics. MBio 2(1), e00301-e00310 (2011).
40. González-Bello C. Discovery of new antibiotics targeting the biosynthesis of aromatic amino acids: structure-based design and simulation studies. Curr. Top. Med. Chem. (2015) (Epub ahead of print).
41. González-Bello C, Castedo L. Progress in type II dehydroquinase inhibitors: from concept to practice. Med. Res. Rev. 27(2), 177-208 (2007).
42. Le Sann C, Gower MA, Abell AD. Inhibitors of types I and II dehydroquinase. Mini-Reviews Med. Chem. 4(7), 747-756 (2004).
43. Abell C. Enzymes that exploit imines-one way or the other. Biochem. Soc. Trans. 26(3), 310-315 (1998).
44. Knowles JR. Enzyme catalysis: not different, just better. Nature 350(6314), 121-124 (1991).
45. Bugg T. An Introduction to Enzyme and Coenzyme Chemistry. Blackwell Science, Oxford, UK 37 (1997).
46. Bugg TD H. Chemical strategies for enzyme catalysis: chemical strategies. In: Wiley Encyclopedia of Chemical Biology. Wiley, NY, USA, 774-784 (2008).
47. Eliot AC, Kirsch FJ. Pyridoxal phosphate enzymes: mechanistic, structural, and evolutionary considerations. Ann. Rev. Biochem. 73, 383-415 (2004).
48. Amadasi A, Bertoldi M, Contestabile R et al. Pyridoxal 5'-phosphate enzymes as targets for therapeutic agents. Curr. Med. Chem. 14(12), 1291-1324 (2007).
49. Butler JR, Alworth WL, Nugent MJ. Mechanism of dehydroquinase catalyzed dehydration. 1. Formation of a Schiff-base intermediate. J. Am. Chem. Soc. 96(5), 1617-1618 (1974).
50. Gourley DG, Shrive AK, Polikarpov I et al. The two types of 3-dehydroquinase have distinct structures but catalyse the same overall reaction. Nat. Struct. Biol. 6(6), 521-525 (1999).
51. Harris J, Kleanthous C, Coggings JR, Hawkins AR, Abell C. Different mechanistic and stereochemical courses for the reactions catalysed by type I and type II dehydroquinases. J. Chem. Soc. Chem. Commun. 1080-1081 (1993).
52. Krell T, Horsbourgh MJ, Cooper A, Kelly SM, Coggins JR. Localization of the active site of type II dehydroquinases. J. Biol. Chem. 271(40), 24492-24497 (1996).
53. Deka RK, Kleanthous C, Coggins JR. Identification of the essential histidine residue at the active site of Escherichia coli dehydroquinase. J. Biol. Chem. 267(31), 22237-22242 (1992).
54. Nichols CE, Lockyer M, Hawkins AR, Stammers DK. Crystal structures of Staphylococcus aureus type I dehydroquinase from enzyme turnover experiments. Proteins 56(3), 625-628 (2004).
55. Leech AP, James R, Coggins JR, Kleanthous C. Mutagenesis of active site residues in type I dehydroquinase from Escherichia coli. J. Biol. Chem. 270(43), 25827-25836 (1995).
56. Leech AP, Boetzel R, McDonald C et al. Re-evaluating the role of His143 in the mechanism of type I dehydroquinase from Escherichia coli using two-dimensional 1H, 13C NMR. J. Biol. Chem. 273(16), 9602-9607 (1998).
57. Light SH, Minasov G, Shuvalova L et al. Insights into the mechanism of type I dehydroquinate dehydratases from structures of reaction intermediates. J. Biol. Chem. 286(5), 3531-3539 (2011).
58. Pan Q, Yao Y, Li Z-S. New insights into the mechanism of the Schiff base formation catalyzed by type I dehydroquinate dehydratase from S. enterica. Theor. Chem. Acc. 131, 1204 (2012).
59. Yao Y, Li ZS. New insights into the mechanism of the Schiff base hydrolysis catalyzed by type I dehydroquinate dehydratase from S. enterica: a theoretical study. Org. Biomol. Chem. 10(35), 7037-7044 (2012).
60. Yao Y, Li ZS. The reaction mechanism for dehydratation process catalyzed by type I dehydroquinate dehydratase from Gram-negative Salmonella enterica. Chem. Phys. Lett. 519-520, 100-104 (2012).
61. Nichols CE, Lockyer M, Hawkins AR, Stammers DK. Crystal structures of Staphylococcus aureus type I dehydroquinase from enzyme turnover experiments. Proteins 56(3), 625-628 (2004).
62. Light SH, Antanasijevic A, Krishna SN, Caffrey M, Anderson WF, Lavie A. Crystal structures of type I dehydroquinase dehydratase in complex with quinate and shikimate suggest a novel mechanism of Schiff base formation. Biochemistry 53(5), 872-880 (2014).
63. Kleanthous C, Reilly K, Cooper A, Kelly S, Price NC, Coggins JR. Stabilization of the shikimate pathway enzyme dehydroquinase by covalently bound ligand. J. Biol. Chem. 266(17), 10893-10898 (1991).
64. Reilly A, Morgan P, Davia K et al. Product-induced stabilization of tertiary and quaternary structure in Escherichia coli dehydroquinase. J. Biol. Chem. 269(8), 5523-2236 (1994).
65. Maneiro M, Peón A, Lence E et al. Insights into substrate binding and catalysis in bacterial type I dehydroquinase. Biochem. J. 462(3), 415-424 (2014).
66. Light SH, Minasov G, Shuvalova L et al. A conserved surface loop in type I dehydroquinase dehydratases positions an active site arginine and functions in substrate binding. Biochemistry 50(12), 2357-2363 (2011).
67. Harris JM, Watkins WJ, Hawkins AR, Coggins JR, Abell C. Comparison of the substrate specificity of type I and type II dehydroquinases with 5-deoxy-and 4,5-dideoxy-dehydroquinic acid. J. Chem. Soc. Perkin Trans. I 2371-2377 (1996).
68. European Bioinformatics Institute. Clustal Omega. www.ebi.ac.uk/Tools/msa/clustalo.
69. Bugg TD H, Abell C, Coggins JR. Affinity labelling of E. coli dehydroquinase. Tetrahedron Lett. 29, 6783-6786 (1998).
70. Manthey MK, González-Bello C, Abell C. Synthesis of (2R)-2-bromodehydroquinic acid and (2R)-2-fluorodehydroquinic acid. J. Chem. Soc. Perkin Trans. 1 625-628 (1997).
71. González-Bello C, Harris JM, Manthey MK, Coggins JR, Abell C. Irreversible inhibition of type I dehydroquinase by substrates for type II dehydroquinase. Bioorg. Med. Chem. Lett. 10(5), 407-409 (2000).
72. González-Bello C, Manthey MK, Harris JH, Hawkins AR, Coggins JR, Abell C. Synthesis of 2-bromo-and 2-fluoro-3-dehydroshikimic acids and 2-bromo-and 2-fluoroshikimic acids using synthetic and enzymatic approaches. J. Org. Chem. 63(5), 1591-1597 (1998).
73. Tizón L, Maneiro M, Peón A et al. Irreversible covalent modification of type I dehydroquinase with a stable Schiff base. Org. Biomol. Chem. 13(3), 706-716 (2015).
74. Ratia K, Light SH, Antanasijevic A, Anderson WF, Caffrey M, Lavie A. Discovery of selective inhibitors of the Clostridium difficile dehydroquinate dehydratase. PLoS ONE 9, e89356 (2014).
75. Cheung VW N, Xue B, Hernadez-Valladares M et al. Identification of polyketide inhibitors targeting 3-dehydroquinate dehydratase in the shikimate pathway of Enterococcus faecalis. PLoS ONE 9, e103598 (2014).
76. Singh J, Petter RC, Baillie TA, Whitty A. The resurgence of covalent drugs. Nat. Rev. 10(4), 307-317 (2011).
77. Johnson DS, Weerapana E, Cravatt BF. Strategies for discovering and derisking covalent, irreversible enzyme inhibitors. Future Med. Chem. 2(6), 949-964 (2010).